Serum levels of the incretin-like peptide 26RFa are diminished in women living with obesity and diabetes and restored after sleeve gastrectomy: Results from the prospective pilot RFa-Ba-S study.
26RFa
QRFP
human
obesity
sleeve gastrectomy
type 2 diabetes
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
30 Sep 2024
30 Sep 2024
Historique:
revised:
28
07
2024
received:
13
05
2024
accepted:
28
07
2024
medline:
1
10
2024
pubmed:
1
10
2024
entrez:
1
10
2024
Statut:
aheadofprint
Résumé
To investigate the evolution of the incretin-like peptide 26RFa in a prospective cohort of women living with obesity with or without type 2 diabetes (T2D) before and after sleeve gastrectomy (SG). In this study, a total of 61 women were divided into three groups: women living with severe obesity without T2D (WlwOB group), women living with severe obesity and T2D (WlwOB-T2D group) and lean healthy volunteers (control group). Serum 26RFa concentrations were measured using a 26RFa enzyme-linked immunosorbent assay developed specifically for this study during meal tests before SG, and 30 and 180 days after SG. At baseline, serum 26RFa levels were reduced in the WlwOB (P < .05) and WlwOB-T2D (P < .01) groups compared with controls. In the WlwOB-T2D group, fasting 26RFa levels were found to increase throughout the entire follow-up period up to 6 months after the SG (P < .001). During the meal tests, serum 26RFa levels increased, especially in the WlwOB-T2D group at baseline. At the end of the follow-up, the profile of 26RFa concentrations obtained during the meal test in patients with severe obesity and T2D was similar to that of the controls. This prospective clinical study provides the first evidence that circulating 26RFa is altered mainly in WlwOB-T2D, and that these defects are partially reversed after SG.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : CHU Rouen
Informations de copyright
© 2024 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
Ruze R, Liu T, Zou X, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol (Lausanne). 2023;14:1161521.
Shibib L, Al‐Qaisi M, Ahmed A, et al. Reversal and remission of T2DM: an update for practitioners. Vasc Health Risk Manag. 2022;18:417‐443.
Lampropoulos C, Alexandrides T, Tsochatzis S, Kehagias D, Kehagias I. Are the changes in gastrointestinal hormone secretion necessary for the success of bariatric surgery? A critical review of the literature. Obes Surg. 2021;31:4575‐4584.
Chartrel N, Dujardin C, Anouar Y, et al. Identification of 26RFa, a hypothalamic neuropeptide of the RFamide peptide family with orexigenic activity. Proc Natl Acad Sci U S A. 2003;100:15247‐15252.
Takayasu S, Sakurai T, Iwasaki S, et al. A neuropeptide ligand of the G protein‐coupled receptor GPR103 regulates feeding, behavioral arousal, and blood pressure in mice. Proc Natl Acad Sci U S A. 2006;2006(103):7438‐7443.
Bruzzone F, Lectez B, Tollemer H, et al. Anatomical distribution and biochemical characterization of the novel RFamide peptide 26RFa in the human hypothalamus and spinal cord. J Neurochem. 2006;99:616‐627.
Bruzzone F, Lectez B, Alexandre D, et al. Distribution of 26RFa binding sites and GPR103 mRNA in the central nervous system of the rat. J Comp Neurol. 2007;503:573‐591.
Lectez B, Jeandel L, El‐Yamani F‐Z, et al. The orexigenic activity of the hypothalamic neuropeptide 26RFa is mediated by the neuropeptide Y and proopiomelanocortin neurons of the arcuate nucleus. Endocrinology. 2009;50:2342‐2350.
Granata R, Settanni F, Trovato L, et al. RFamide peptides 43RFa and 26RFa both promote survival of pancreatic β‐cells and human pancreatic islets but exert opposite effects on insulin secretion. Diabetes. 2014;63:2380‐2393.
Prévost G, Picot M, Le Solliec M‐A, et al. The neuropeptide 26RFa in the human gut and pancreas: potential involvement in glucose homeostasis. Endocr Connect. 2019;8:941‐951.
Prévost G, Jeandel L, Arabo A, et al. Hypothalamic neuropeptide 26RFa acts as an incretin to regulate glucose homeostasis. Diabetes. 2015;64:2805‐2816.
Prévost G, Arabo A, Le Solliec M‐A, et al. Neuropeptide 26RFa (QRFP) is a key regulator of glucose homeostasis and its activity is markedly altered in obese/hyperglycemic mice. Am J Physiol Endocrinol Metab. 2019;317:E147‐E157.
El‐Mehdi M, Takhlidjt S, Khiar F, et al. Glucose homeostasis is impaired in mice deficient in the neuropeptide 26RFa (QRFP). BMJ Open Diabetes Res Care. 2020;8:e000942.
Le Solliec M‐A, Arabo A, Takhlidjt S, et al. Interactions between the regulatory peptide 26RFa (QRFP) and insulin in the regulation of glucose homeostasis in two complementary models: the high fat 26RFa‐deficient mice and the streptozotocin insulin‐deficient mice. Neuropeptides. 2023;98:102326.
El Mehdi M, Takhlidjt S, Devère M, et al. The 26RFa (QRFP)/GPR103 neuropeptidergic system in mice relays insulin signalling into the brain to regulate glucose homeostasis. Diabetologia. 2022;65:1198‐1211.
Le Solliec M‐A, Arabo A, Takhlidjt S, et al. Acute but not chronic central administration of the neuropeptide 26RFa (QRFP) improves glucose homeostasis in obese/diabetic mice. Neuroendocrinology. 2022;112:1104‐1115.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta‐cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412‐419.
Galusca B, Jeandel L, Germain N, et al. Orexigenic neuropeptide 26RFa: new evidence for an adaptive profile of appetite regulation in anorexia nervosa. J Clin Endocrinol Metab. 2012;97:2012‐2018.
Leprince J, Bagnol D, Bureau R, et al. The Arg‐Phe‐amide peptide 26RFa/QRFP and its receptor. IUPHAR review. Br J Pharmacol. 2017;174:3573‐3607.
Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5‐21.
Calanna S, Christensen M, Holst JJ, et al. Secretion of glucagon‐like peptide‐1 in patients with type 2 diabetes mellitus: systematic review and meta‐analyses of clinical studies. Diabetologia. 2013;56:965‐972.
Calanna S, Christensen M, Holst JJ, et al. Secretion of glucose‐dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta‐analysis of clinical studies. Diabetes Care. 2013;36:3346‐3352.
Pham S, Gancel A, Scotte M, et al. Comparison of the effectiveness of four bariatric surgery procedures in obese patients with type 2 diabetes: a retrospective study. J Obes. 2014;2014:638203.
Nosso G, Griffo E, Cotugno M, et al. Comparative effects of roux‐en‐Y gastric bypass and sleeve gastrectomy on glucose homeostasis and Incretin hormones in obese type 2 diabetic patients: a one‐year prospective study. Horm Metab Res. 2016;48:312‐317.
Nauck MA, Müller TD. Incretin hormones and type 2 diabetes. Diabetologia. 2023;66:1780‐1795.
Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsbøll T. Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96:737‐745.
Albaugh VL, He Y, Münzberg H, Morrison CD, Yu S, Berthoud HR. Regulation of body weight: lessons learned from bariatric surgery. Mol Metab. 2023;68:101517.
Cavin J‐B, Couvelard A, Lebtahi R, et al. Differences in alimentary glucose absorption and intestinal disposal of blood glucose after roux‐en‐Y gastric bypass vs. sleeve gastrectomy. Gastroenterology. 2016;150:454‐464.e9.